Clinical trials
Clinical Study clinical trials
Below are recruiting clinical study clinical trials, each written for real people, not researchers. We’re tracking 1,806 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04704947RecruitingPhase 3
Beta blockers and fracture risk in osteoporosis
This study tests whether using beta blocker blood pressure medicines affects the risk of fractures in people with osteoporosis. It may help doctors understand which medication choices lower fracture risk.
TantaAges 50 years+ - NCT05477849RecruitingPhase 1
Study drug for people with advanced solid tumors
This Phase 1 trial tests the safety and early effects of VG2025 in people with advanced solid cancers that have stopped responding to standard treatments. It’s mainly looking for side effects and how the body processes the drug, and it may offer a new option when other treatments haven’t worked.
Hangzhou, ZhejiangAges 18–75 - NCT04969354RecruitingPhase 1
CAIX-targeted CAR-T therapy for advanced kidney cancer
This early-phase study tests a lab-made immune treatment (CAIX-targeted CAR-T cells) for advanced kidney cancer that has not gone away with standard targeted therapy or immunotherapy. If eligible, the goal is to see if the treatment can safely shrink the cancer and improve outcomes.
Xuzhou, JiangsuAges 18–70 - NCT02142946Recruiting
Track balance and walking in people with MS
This study measures how well you can balance and walk over time. It may help researchers understand balance problems in multiple sclerosis and how they change with movement.
BaselAges 18–80 - NCT05166070RecruitingEarly Phase 1
RD133 for mesothelin-positive tumors after prior treatments
This early-phase study tests RD133, an experimental treatment, in adults whose solid tumors are mesothelin-positive and have come back or not responded to prior standard therapies. It aims to see how well RD133 can control these cancers and what side effects it causes.
Nanjing, JiangsuAges 18 years+ - NCT04137237Recruiting
Study of carbon hand and wrist implants after surgery
This trial follows people who receive a special hand or wrist implant made of pyrocarbon (a strong, durable material). It aims to measure outcomes over time to see how well the implant works and how patients do functionally.
LyonAges 18 years+ - NCT06945523RecruitingPhase 1
CAR-T cell therapy for CEA-positive advanced lung cancer
This trial tests a treatment using your own immune cells, modified to target a protein called CEA on lung cancer cells. It's for people with advanced lung cancer that has gotten worse after at least one prior treatment.
Wuhan, HubeiAges 18 years+ - NCT07113795Enrolling by invitationEarly Phase 1
Chinese medicine and stem cells for Crohn's fistula
This trial tests a new approach that combines traditional Chinese medicine with stem cells to treat complex anal fistulas caused by Crohn's disease. It may help people whose Crohn's is not very active and who have not had major fistula surgery before.
Nanjing, JiangsuAges 18–60 - NCT06208410RecruitingPhase 1/Phase 2
JS105 plus other treatments for advanced solid tumors
This trial tests a new drug called JS105 combined with other anti-cancer therapies for people with certain advanced breast, ovarian, endometrial, or cervical cancers. It aims to find out if these combinations are safe and effective.
Zhengzhou, HenanAges 18–75 - NCT06189963RecruitingPhase 1/Phase 2
Cell therapy trial for moderate Alzheimer's disease
This trial tests a new immune cell therapy (SNK01) for people with moderate Alzheimer's disease. The goal is to see if it can slow down memory and thinking decline.
Glendale, CaliforniaAges 40–85 - NCT07112209Enrolling by invitation
Rezvilutamide plus chemo for prostate cancer
This study tests a new combination treatment (Rezvilutamide plus docetaxel chemotherapy) for men with advanced prostate cancer that has stopped responding to abiraterone. The goal is to see if this combination can help control the cancer.
Guangzhou, GuangdongAges 18 years+ - NCT06197139RecruitingPhase 1
Study of a new targeted radiation therapy for advanced solid tumors
This trial tests an investigational drug called [177Lu]Lu-XT117, which delivers a small dose of radiation directly to cancer cells that have a specific protein called FAP. It is for people with advanced solid tumors who have run out of standard treatment options or cannot tolerate them.
GuangzhouAges 18 years+ - NCT07139067RecruitingPhase 1
YK1101 for advanced solid tumors
This trial tests a new cell therapy called YK1101 for people with advanced solid tumors that have not responded to standard treatment. It targets a specific protein (MAGE-A4) on cancer cells and requires a matching genetic type called HLA-A*11:01.
BeijingAges 18–75 - NCT06434597RecruitingPhase 2
Study of SPH5030 for HER2-positive advanced colorectal or bile duct cancer
This study tests a new medication (SPH5030) for people with advanced colorectal or biliary tract cancer whose tumors have a specific marker called HER2. It may offer a treatment option if previous therapies have stopped working.
BeijingAges 18 years+ - NCT04905056RecruitingPhase 2
Ablation treatment for lung ground-glass nodules that don’t go away
This Phase 2 trial studies whether a procedure called “ablation” is safe and effective for certain lung cancers that appear as ground-glass spots on CT scans and do not improve after 3 months. It may help people who cannot fully have surgery for their condition.
Shanghai, Shanghai MunicipalityAges 18–85 - NCT06879145RecruitingPhase 2/Phase 3
Study of SHR-A2102 and Adebrelimab for muscle-invasive bladder cancer
This trial tests a combination of two drugs, SHR-A2102 and Adebrelimab, for people with muscle-invasive bladder cancer that hasn't spread. The goal is to see if this treatment can help control the cancer.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06857279RecruitingPhase 2
Testing HLX43 for advanced head and neck cancer
This trial tests an investigational drug called HLX43 for people with advanced head and neck cancer that has returned or spread. It aims to see if the drug can shrink tumors or slow cancer growth.
Jinan, ShandongAges 18–75 - NCT06210490RecruitingPhase 2
Antibody-drug combo with radiation for HER2+ UTUC after surgery
This trial tests a combination of an antibody-drug conjugate (Disitamab Vedotin) plus radiation therapy after surgery to prevent upper tract urothelial cancer from coming back. It is for patients with HER2-positive tumors and high-risk features who cannot receive cisplatin chemo.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06189495RecruitingPhase 2
Study of Genakumab for lung scarring from connective tissue disease
This study tests a new injected medication (Genakumab) for people with connective tissue disease-related lung scarring. It aims to see if it helps stabilize or improve lung function safely.
Beijing, Beijing MunicipalityAges 18–75 - NCT06825494RecruitingPhase 1/Phase 2
Study of a new drug for advanced solid tumors
This trial tests a new medication for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Hefei, AnhuiAges 18 years+ - NCT07308782RecruitingPhase 2
Testing a new HIV treatment in people not yet on therapy
This trial is testing an experimental HIV pill called CL-197. It's for people with HIV who have never taken any HIV medicines before. The study lasts about 2 weeks and aims to see how the drug works in the body.
BeijingAges 18–60 - NCT06213038RecruitingPhase 1
Study of SKG0106 for wet age-related macular degeneration
This study tests a new medicine called SKG0106, given as an injection into the eye, for people with wet age-related macular degeneration (AMD). It aims to see if it is safe and effective in treating the leaky blood vessels that cause vision loss.
BeijingAges 50 years+ - NCT06362577Recruiting
HIFU vs Robot Surgery for Localized Prostate Cancer
This trial compares two treatments for localized prostate cancer: high-intensity focused ultrasound (HIFU) using a device called Sonablate and robot-assisted surgery. It aims to see which works better and has fewer side effects.
Shanghai, Shanghai MunicipalityAges 40 years+ - NCT07415863RecruitingPhase 1/Phase 2
Study of SYS6043 for advanced solid tumors
This trial tests a new drug, SYS6043, for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can help shrink or control the tumor.
Beijing, Beijing MunicipalityAges 18–75
Hear when a new Clinical Study trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for clinical study?
- Yes. Clin2 currently lists 1,806 recruiting clinical study studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a clinical study trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a clinical study trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.